Lina Wang1, Leonelo E Bautista2. 1. Key Laboratory of Environmental Medicine Engineering, Ministry of Education, Department of Epidemiology and Biostatistics, School of Public Health, Southeast University, Nanjing, China and Department of Population Health Sciences, University of Wisconsin in Madison, Madison, WI, USA Key Laboratory of Environmental Medicine Engineering, Ministry of Education, Department of Epidemiology and Biostatistics, School of Public Health, Southeast University, Nanjing, China and Department of Population Health Sciences, University of Wisconsin in Madison, Madison, WI, USA. 2. Key Laboratory of Environmental Medicine Engineering, Ministry of Education, Department of Epidemiology and Biostatistics, School of Public Health, Southeast University, Nanjing, China and Department of Population Health Sciences, University of Wisconsin in Madison, Madison, WI, USA lebautista@wisc.edu.
Abstract
BACKGROUND: Experimental studies suggest oxidative stress could lead to the development of hypertension. Serum bilirubin is a major contributor to the antioxidant capacity in blood plasma and has been identified as an independent cardiovascular risk factor in cohort studies. However, data on the relationship between bilirubin and blood pressure are scarce and inconclusive. METHODS: We analysed data from the National Health and Nutrition Examination Surveys (NHANES) 1999-2012 (N=31069). Fifty multiple imputed data sets were generated and analysed to avoid selection/confounding bias due to excluding individuals/variables with missing values. A minimal sufficient adjustment set of variables (MSAS) needed to estimate the unconfounded effect of bilirubin on blood pressure and hypertension (systolic/diastolic blood pressure ≥ 140/90 mmHg or using antihypertensive medication) was identified using the back-door criterion and included in all regression models. RESULTS: After adjustment for the MSAS variables, systolic blood pressure decreased progressively up to -2.5 mmHg (p<0.001) and the prevalence of hypertension was up to 25% lower (P<0.001) in those with bilirubin ≥ 1.0 mg/dl-the highest two deciles-compared with those with 0.1-0.4 mg/dl-the lowest decile. Sensitivity analyses showed these results were unlikely to be explained by residual confounding or selection bias. CONCLUSIONS: High serum bilirubin may decrease the risk of hypertension by inactivating and inhibiting the synthesis of reactive oxygen species in vascular cells. Strategies to boost the bioavailability of circulating and tissue bilirubin or to mimic bilirubin's antioxidant properties could have a significant impact on prevention and control of hypertension as well as coronary heart disease.
BACKGROUND: Experimental studies suggest oxidative stress could lead to the development of hypertension. Serum bilirubin is a major contributor to the antioxidant capacity in blood plasma and has been identified as an independent cardiovascular risk factor in cohort studies. However, data on the relationship between bilirubin and blood pressure are scarce and inconclusive. METHODS: We analysed data from the National Health and Nutrition Examination Surveys (NHANES) 1999-2012 (N=31069). Fifty multiple imputed data sets were generated and analysed to avoid selection/confounding bias due to excluding individuals/variables with missing values. A minimal sufficient adjustment set of variables (MSAS) needed to estimate the unconfounded effect of bilirubin on blood pressure and hypertension (systolic/diastolic blood pressure ≥ 140/90 mmHg or using antihypertensive medication) was identified using the back-door criterion and included in all regression models. RESULTS: After adjustment for the MSAS variables, systolic blood pressure decreased progressively up to -2.5 mmHg (p<0.001) and the prevalence of hypertension was up to 25% lower (P<0.001) in those with bilirubin ≥ 1.0 mg/dl-the highest two deciles-compared with those with 0.1-0.4 mg/dl-the lowest decile. Sensitivity analyses showed these results were unlikely to be explained by residual confounding or selection bias. CONCLUSIONS: High serum bilirubin may decrease the risk of hypertension by inactivating and inhibiting the synthesis of reactive oxygen species in vascular cells. Strategies to boost the bioavailability of circulating and tissue bilirubin or to mimic bilirubin's antioxidant properties could have a significant impact on prevention and control of hypertension as well as coronary heart disease.
Authors: Katherine H Shutta; Raji Balasubramanian; Tianyi Huang; Shaili C Jha; Oana A Zeleznik; Candyce H Kroenke; Lesley F Tinker; Jordan W Smoller; Ramon Casanova; Shelley S Tworoger; JoAnn E Manson; Clary B Clish; Kathryn M Rexrode; Susan E Hankinson; Laura D Kubzansky Journal: Psychoneuroendocrinology Date: 2021-09-20 Impact factor: 4.693
Authors: Jacy T Zanussi; Juan Zhao; Chad A Dorn; Ge Liu; QiPing Feng; WeiQi Wei; Jonathan D Mosley; C Michael Stein; Vivian K Kawai Journal: Clin Pharmacol Ther Date: 2021-10-24 Impact factor: 6.903
Authors: Chaudry N Majeed; Muhammad I Ahmad; Irfan Ahsan; Muhammad A Anees; Sanjay K Maheshwari; Elsayed Z Soliman Journal: Ann Noninvasive Electrocardiol Date: 2019-09-09 Impact factor: 1.468
Authors: Tianyi Huang; Oana A Zeleznik; Elizabeth M Poole; Clary B Clish; Amy A Deik; Justin M Scott; Céline Vetter; Eva S Schernhammer; Robert Brunner; Lauren Hale; JoAnn E Manson; Frank B Hu; Susan Redline; Shelley S Tworoger; Kathryn M Rexrode Journal: Int J Epidemiol Date: 2019-08-01 Impact factor: 7.196
Authors: Setor K Kunutsor; Lyanne M Kieneker; Stephen Burgess; Stephan J L Bakker; Robin P F Dullaart Journal: J Am Heart Assoc Date: 2017-11-13 Impact factor: 5.501